Mousa Shaker A
Albany College of Pharmacy, Albany, NY 12208-3492, USA.
Curr Pharm Des. 2003;9(28):2317-22. doi: 10.2174/1381612033453893.
Cardiovascular and cerebrovascular diseases continue to be leading causes of death throughout the world. Blood platelets play a pivotal role not only in haemostasis but also in the pathogenesis of thrombosis and atherosclerosis, platelet aggregation being an essential step in the formation of either an effective haemostatic plug or an intravascular thrombus. The benefits of various antiplatelet therapies ranging from aspirin, ticlopidine, Clopidogrel, and intravenous platelet GPIIb/IIIa antagonists in various thromboembolic disorders are well documented. Despite of the success of intravenous acute GPIIb/IIIa blockade when given in conjunction with heparin, chronic oral GPIIb/IIIa antagonists with or without aspirin failed in various cardiovascular settings. This review highlights the role of the various antiplatelet therapies in thrombotic disorders as well as future directions.
心血管疾病仍然是全球主要的死亡原因。血小板不仅在止血过程中发挥关键作用，而且在血栓形成和动脉粥样硬化的发病机制中也起着重要作用，血小板聚集是形成有效止血栓或血管内血栓的关键步骤。从阿司匹林、噻氯匹定、氯吡格雷到静脉注射血小板糖蛋白IIb/IIIa拮抗剂等各种抗血小板疗法在各种血栓栓塞性疾病中的益处已有充分记录。尽管静脉注射急性糖蛋白IIb/IIIa阻滞剂与肝素联合使用取得了成功，但无论是否联合使用阿司匹林，慢性口服糖蛋白IIb/IIIa拮抗剂在各种心血管疾病治疗中均告失败。本综述强调了各种抗血小板疗法在血栓性疾病中的作用以及未来的发展方向。
